Table 1.
Descriptive characteristics of the study cohort (n=670)
| Variable | Descriptive statistic |
|---|---|
| Demographics | |
| Age (years, M [SD]) | 42.7 (10.0) |
| Education (years, M [SD]) | 13.5 (2.5) |
| Sex (% male) | 88.36 |
| Ethnicity (%) | |
| Non-Hispanic White | 62.54 |
| Non-Hispanic Black | 18.36 |
| Hispanic | 13.73 |
| Other | 5.37 |
| HIV disease characteristics | |
| Current CD4+ T-cell count (Median, [IQR]) | 404 (190–605.3) |
| On ART (%) | 66.92 |
| Plasma HIV RNA (% detectable)a | 52.69 |
| Months of Exposure to ART (Median, [IQR]) | 25.4 (1.1–80.4) |
| Nadir CD4+ T-cell count (Median, [IQR]) | 148 (24.8–300) |
| AIDS (% Yes) | 62.88 |
| Duration of infection (years, Median [IQR])b | 9.4 (3.9–15.1) |
| Psychiatric Characteristics (% Yes) | |
| Lifetime Major Depressive Disorderc | 50.57 |
| Current Major Depressive Disorderd | 18.97 |
| Lifetime Substance Use Disorderc | 70.10 |
| Current Substance Use Disorderd | 13.65 |
| Current mood symptoms (%) | |
| Mild | 29.53 |
| Moderate | 17.97 |
| Severe | 7.12 |
| NCI (%) | 38.36 |
| VACS Index scores (Median, [IQR]) | 18 (10–34) |
| VACS Index group (%)e | |
| Low | 28.51 |
| Medium | 46.42 |
| High | 25.08 |
| Everyday functioning Outcomes | |
| IADL declines (Median, [IQR]) | 1 (0–3) |
| PAOFI total score (Median, [IQR]) | 3.5 (1–10) |
| Unemployment (%) | 71.60 |
Note.
a
Percent detectable among those on ART
b
n=607
c
n=534
d
n=520,
e
VACS Index group = VACS Index scores were grouped based on IQR; low<10, medium=10–34, high>34.
ART, antiretroviral therapy; IADL, instrumental activities of daily living; NCI, neurocognitive impairment; PAOFI, Patient Assessment of Own Functioning